All In Biotech

Drug Trial Radar · NCT04699591

Compassionate Use of Domperidone for Refractory Gastroparesis

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Apr 2013

Primary completion

Dec 2035

Study completion Dec 2035

Sponsor

Lead sponsor
Jose CocjinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

Conditions

  • GERD
  • Gastroesophageal Reflux
  • Gastroparesis

Interventions

  • DomperidoneDrug

    Domperidone taken 4 times a day, dose based on body weight

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in disease severityTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.